Telbivudine prevents passage of HBV during pregnancy
2 June 2015 | By Victoria White
The antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV), according to a new study...
List view / Grid view
News
Cabazitaxel – carboplatin combination chemotherapy holds promise as treatment for advanced prostate cancer
1 June 2015 | By Victoria White
A new study compared the effectiveness of cabazitaxel alone versus cabazitaxel combined with carboplatin in patients with mCRPC...
EC approves anticancer agent Lenvima for treatment of advanced thyroid cancer
1 June 2015 | By Victoria White
The EC has approved Lenvima in the treatment of adult patients with progressive, locally advanced or metastatic differentiated thyroid carcinoma...
Gazyvaro stalls growth and spread of indolent non-Hodgkin’s lymphoma
1 June 2015 | By Victoria White
Results from a Phase III study show that Gazyvaro provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL)...
Idelalisib in combination with ofatumumab improves progression-free survival in previously-treated patients with chronic lymphocytic leukaemia
1 June 2015 | By Victoria White
Results from a study of idelalisib in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukaemia have been announced...
AstraZeneca presents positive data on AZD9291 in first-line EGFR mutated lung cancer
1 June 2015 | By Victoria White
AstraZeneca has announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of EGFRm advanced non-small cell lung cancer (NSCLC)...
RAPAMUNE becomes first FDA-approved treatment for lymphangioleiomyomatosis (LAM)
1 June 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Pfizer’s RAPAMUNE (sirolimus) in the US for the treatment of lymphangioleiomyomatosis (LAM)...
Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
1 June 2015 | By Victoria White
Roche has announced new results from the Phase II NeoSphere study that assessed a Perjeta regimen in people with HER2-positive early breast cancer...
Trial of new stem cell therapy for dystrophic epidermolysis bullosa (RDEB) gives promising results
1 June 2015 | By
Results from a trial of a new stem-cell based therapy for a rare skin condition, recessive dystrophic epidermolysis bullosa (RDEB), have been published...
Palbociclib more than doubled progression-free survival in Phase 3 trial for patients with HR+, HER2- metastatic breast cancer
1 June 2015 | By Victoria White
Results from a Phase 3 study demonstrate that palbociclib significantly extended progression-free survival in women with HR+HER2- metastatic breast cancer...
Phase III trial demonstrates superior progression-free survival of Opdivo+Yervoy regimen in patients with advanced melanoma
1 June 2015 | By Victoria White
BMS has announced positive results of a Phase III trial evaluating the Opdivo+Yervoy regimen in patients with previously untreated advanced melanoma...
EMA validates Marketing Application for fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) for HIV treatment
29 May 2015 | By Victoria White
Gilead’s MAA for a fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) has been fully validated and is now under evaluation by the EMA..
New clinical research programme launched for the prevention and treatment of blood clots in patients with cancer
29 May 2015 | By VIctoria White
Janssen and Bayer have launched a clinical research programme evaluating rivaroxaban for the prevention and treatment of blood clots in patients with cancer...
Synjardy granted marketing authorisation in the EU for the treatment of adults with type 2 diabetes
28 May 2015 | By Victoria White
Synjardy has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union...
J&J accepts binding offer from Cardinal Health for Cordis
28 May 2015 | By Victoria White
Johnson & Johnson has accepted the 1 March 2015 binding offer from Cardinal Health to acquire its Cordis business for an approximate value of $2 billion...
